Lack of transmission of TT virus through immunoglobulins by Azzari, Chiara et al.
LACK OF TRANSMISSION OF TTV THROUGH IVIG
Volume 41, December 2001   TRANSFUSION   1505www.transfusion.org
BACKGROUND: A high prevalence of TT virus (TTV) in-
fection has been found in patients who received blood or
blood components. Viral DNA was demonstrated in com-
mercial preparations of FVIII and F IX, but very few data
have been reported on immunoglobulins. The risk of TTV
infection associated with intramuscular or IV immunoglobu-
lin administration is unclear.
STUDY DESIGN AND METHODS: The prevalence of TTV
infection in a group of patients undergoing lifelong therapy
because of congenital immunodeficiency has been evalu-
ated in a long term follow-up (median, 6 years). Seventeen
patients with congenital immunodeficiency receiving
monthly administration of IVIG were included in the study.
TTV DNA was repeatedly evaluated by PCR in serum
samples from each patient during the follow-up. Research
of antibodies against TTV was not applicable, as the pa-
tients studied were unable to produce antibodies. The
presence of TTV was also evaluated in 15 IVIG lots.
RESULTS: The total amount of immunoglobulin adminis-
tered was 18,773 g. TTV infection was not found in any pa-
tients included in the study. None of the 15 immunoglobulin
preparations analyzed was found positive for TTV DNA.
CONCLUSION: Despite the high prevalence of TTV in
blood donors, commercial immunoglobulins are safe and
unable to transmit TTV.
A novel DNA virus, TT virus (TTV), has been impli-cated as a cause of posttransfusion hepatitis.1 Theexistence of several genotypes of the virus hasbeen shown by studies,2,3 and, as with HCV, mul-
tiple variants may be found in the same patients.4,5 In all the
variants, the noncoding region of the viral genome is the most
highly conserved. On the other hand, the sequence of the
coding region, which is more variable, is usually used to di-
vide the virus into different genotypes. At present, more than
15 genotypes have been described.6 Correlation between
genotypes and the geographic source of the virus has not
been shown.4 A high prevalence of TTV infection has been
found in patients who received blood or blood components.7,8
Viral DNA was demonstrated in commercial preparations
of FVIII and F IX.8 Other parenterally transmitted viruses such
as HCV, have been shown in intramuscular immunoglobulin
(IMIG) or IVIG preparations,9,10 and sporadic outbreaks of
HCV infections occurred before 1994.11
Recently, the presence of TTV DNA was confirmed in
IMIG batches,12 but very few data have been reported on
IVIG. Little is known about the risk of TTV infection in asso-
ciation with IMIG or IVIG administration. The aim of the
present study was to investigate the prevalence of TTV in-
fection in a group of patients undergoing lifelong therapy with




Seventeen patients (12 males, 5 females) with congenital
immunodeficiency were included in the study. All the patients
received monthly doses of IVIG (Endobulin, Baxter, Pisa, Italy;
IgVENA, Sclavo-Chiron, Siena, Italy; or Venogamma, Alfa
Wassermann, Pescara, Italy). Two patients (men, 29 and 30
years old) had received IMIG before IVIG became available.
The median age of the patients at the time of the study was
50 months (range, 17 months–30 years). All the patients had
been followed since they first received immunoglobulins. The
median follow-up on the patients studied was 6 years (range,
12 months–25 years). In Table 1, the immunologic disease
diagnosed, the age and sex of the patients, and the duration
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of IVIG therapy are reported. For each patient, at least two
serum samples were analyzed during the follow-up. All of
the sera analyzed had been stored at –80°C and not thawed
before testing for TTV DNA.
Detection of TTV sequences
Total DNA was extracted from 200 µL of serum by use of a
blood kit (QIAamp, QIAGEN Ltd, Crawley, UK) and resus-
pended in 50 µL of elution buffer. Total DNA was also extracted
from 200 µL of 15 samples of IVIG (2 archived and 3 current
preparations for each of Endobulin, IgVENA, and
Venogamma). Samples of IMIG were not available for testing.
TTV DNA was amplified by semi-nested PCR with TTV-
specific primers derived from a conserved region of the pub-
lished sequences.13,14 Specifically, TTV DNA was amplified by
PCR in a thermal cycler (2400, Perkin-Elmer, Emeryville, CA)
by the following protocol: 35 cycles at 94°C for 30 seconds, at
58°C for 30 seconds, and at 72°C for 45 seconds and 1 cycle at
72°C for 7 minutes. The reaction conditions were 20 pmol of
each primer (Primer A: sense, 5′-ACA GAC AGA GGA GAA
GGC AAC ATG-3′, position 1900-1923 from ORF-1; Primer
B: antisense, 5′-CTG GCA TTT TAC CAT TTC CAA AGT-3′,
position 2185-2161) and 2.5 U of Taq polymerase (Polymed,
Milan, Italy) in a 50-µL reaction volume. Five µL of the prod-
ucts of amplification was amplified in a second round of PCR
by use of a semi-nested primer set (primer C: sense, 5′-GGC
AAC ATG TTA TGG ATA GAC TGG-3′, position 1915-1938;
antisense, the same Primer B) under the same conditions
described above. The length of the amplicons obtained was
270 bp. Multiple positive and negative controls were included
in each PCR assay. PCR products were
analyzed in a 2-percent agarose gel elec-
trophoresis with ethidium bromide
staining.7 For IVIG samples and for
pooled sera that were negative for TTV,
10 µL of a positive serum sample was
added and TTV testing was repeated to
exclude the presence of possible Taq in-
hibitors. Research on antibodies against
TTV was not applicable, as the patients
studied were unable to produce immu-
noglobulins.
RESULTS
For each patient, the number of immu-
noglobulin administrations, the amount
of immunoglobulin received (in grams),
and the number of TTV PCRs performed
are reported in Table 2. The total num-
ber of parenteral immunoglobulin ad-
TABLE 1. Diagnosis of immunologic disease, age, sex, and duration
of IVIG therapy in 17 patients with congenital immunodeficiency who
received monthly IVIG doses
Age Duration of IVIG
Patient Diagnosis (months) Sex therapy (months)
1 X-linked agammaglobulinemia 360 M 300 *
2 X-linked agammaglobulinemia 344 M 288 *
3 X-linked agammaglobulinemia 145 M 139
4 X-linked agammaglobulinemia 50 M 044
5 X-linked agammaglobulinemia 18 M 011
6 Severe combined immunodeficiency 74 M 068
7 Autosomal agammaglobulinemia 142 F 138
8 Autosomal agammaglobulinemia 127 F 111
9 Common variable immunodeficiency 204 F 061
10 Common variable immunodeficiency 170 M 121
11 Transient hypogammaglobulinemia of infancy 30 F 026
12 Transient hypogammaglobulinemia of infancy 25 M 021
13 Transient hypogammaglobulinemia of infancy 24 M 018
14 Transient hypogammaglobulinemia of infancy 24 M 020
15 Transient hypogammaglobulinemia of infancy 19 M 015
16 Transient hypogammaglobulinemia of infancy 18 F 012
17 Transient hypogammaglobulinemia of infancy 17 M 013
* Administration of IVIG was started in 1984; before that date, the patients received
280 g (Patient #1) and 310 g (Patient #2) of IMIG.
TABLE 2. Number of immunoglobulin administrations, amount of immunoglobulins received (g), and number of TTV
PCRs performed in 17 patients with congenital immunodeficiency who received monthly IVIG doses
Number of Number of Age of
immunoglobulin   Immunoglobulins TTV PCRs patients at
Patient administrations received (g) performed TTV PCR (months)
1 302 6060 8 144, 168, 212, 237, 298, 331, 348, 357
2 283 5100 5 91, 163, 220, 275, 343
3 145 1210 7 23, 46, 88, 106, 117, 132, 141
4 42 289 4 12, 22, 29, 48
5 14 43 2 10, 16
6 74 481 4 13, 24, 36, 70
7 148 1040 7 37, 48, 61, 85, 99, 106, 138
8 123 1081 7 24, 38, 45, 68, 93, 104, 120
9 65 1500 4 145, 168, 181, 201
10 129 1502 7 50, 63, 77, 98, 123, 138, 163
11 26 98 3 6, 10, 28
12 21 74 3 7, 13, 23
13 18 77 2 9, 15
14 18 72 3 8, 20
15 14 50 2 6, 17
16 14 43 2 7, 18
17 9 53 2 5, 16
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ministrations in the 17 patients was 1445 and the total
amount of immunoglobulin administered was 18,773 g. The
median number of TTV PCRs performed in each patient was
4 (range, 2-8).
TTV DNA was not found in any of the serum samples
analyzed. None of the 15 immunoglobulin preparations ana-
lyzed was found positive for TTV DNA. All IVIG samples and
pooled sera to which positive serum was added were found
positive for TTV DNA.
DISCUSSION
The present results show that TTV is not transmitted through
IVIG: more than 18,000 g of immunoglobulin was adminis-
tered to the patients, and no case of TTV infection was re-
corded. These results could be due to the absence of TTV in
plasma pools. However, with the same primers, the preva-
lence of TTV in a normal population of blood donors in Italy
is 22 percent.7 Therefore, given the high prevalence of TTV
infection in blood donors and plasma pools7,12 and the huge
number of transfusions received by the patients, the absence
of infection is more likely due to the removal or inactivation
of TTV by the manufacturing process. This is confirmed by
studies conducted by other authors. Pisani et al.,12 with a set
of primers derived from a conserved region of TTV, could
detect TTV DNA in 70 percent of four plasma pools derived
from blood donors from different countries, whereas IVIG
was consistently negative with the same primer set. The same
authors demonstrated that the large majority of FVIII con-
centrates and a high number of IMIG batches are TTV posi-
tive. The results obtained in the present research confirm
that, unlike FVIII concentrates, IVIG preparations are free
of TTV sequences.14
At present, most IVIG products released in the world
are subjected to a virus-inactivation step using S/D treatment
or pasteurization.9,10,15-17 We cannot exclude that other meth-
ods of virus inactivation may be less effective in eliminating
TTV or other blood-borne viruses. Six patients were already
receiving IVIG substitute therapy before 1994, and the present
results suggest that TTV was probably inactivated also by the
procedures performed before that time. Moreover, as has
previously been described for other nonenveloped DNA vi-
ruses,17 TTV virus may be removed during a purification step
before S/D treatment or pasteurization.
Recently, it has been suggested that the use of different
primer sets or longer times of extension or annealing during
PCR may increase the sensitivity of the method, but the same
authors also suggested the need for development of inter-
national standards.18
The immunologic disorders of the patients studied, who
were unable to produce immunoglobulins, precluded the
evaluation of TTV antibodies. Therefore, the present data
cannot exclude, in older patients, transient TTV viremia.
However, this possibility seems extremely unlikely, because,
as has been repeatedly shown, TTV DNA persists through a
follow-up of years in infected patients.7,19,20 In particular, in
multiply transfused patients, a chronic infection may be
observed in more than 80 percent of the cases,7,20 and TTV
DNA has been shown to persist in serum samples taken up
to 6 years apart in individual patients.19 Moreover, virus clear-
ance is usually decreased in immunodeficient patients; there-
fore, the hypothesis of transient viremia and resolution of
TTV infection is even more unlikely in these patients than in
an immunocompetent host.
In conclusion, the present findings suggest that the frac-
tionation process and stringent procedures to inactivate vi-
ruses make commercial IVIG safe and unable to transmit TTV.
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